Is GSK plc (GSK) an Undervalued Defensive Stock for 2025?
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks ...
FierceBiotech8d
GSK, Merck and Pfizer in Ab&B's sights as Chinese vaccine biotech files for IPO
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
GSK announces new drug applications accepted for review in China, Japan
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...
The Motley Fool2y
Investing in Vaccine Stocks
GSK (GSK 0.86%) wasn't a major player in the ... However, the company also markets other products, including smallpox and mpox vaccine ACAM2000. Keith Speights has positions in Pfizer.
pharmaphorum2d
GSK says $2.2bn settlement resolves most Zantac litigation
as well as other ranitidine products sold by other companies – increased the risk of cancer. GSK has steadfastly denied that Zantac causes cancer, pointing to the lack of any reliable evidence ...
VentureBeat17d
Hallucinations in AI: How GSK is addressing a critical problem in drug development
In fact, this is a broader industry trend, not only across healthcare, but other verticals ... the system to produce insights that align with healthcare’s strict standards. GSK’s second ...
GSK announces EMA to review the regulatory application of Shingrix
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...